Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

543.90 -27.48 (-4.81%)
Delayed Quote Updated: 2:12 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
From United Therapeutics
Via Business Wire
News headline image
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Acquires Thymmune Therapeutics
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.